Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice

被引：0
|
作者：
Annemarie B. van der Aart-van der Beek
Hiddo J. L. Heerspink
机构：
[1] University of Groningen,Clinical Pharmacy and Pharmacology
来源：
Nature Reviews Nephrology | 2020年 / 16卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.
引用
收藏
页码：433 / 434
页数：1
相关论文
共 50 条
  • [1] Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
    van der Aart-van der Beek, Annemarie B.
    Heerspink, Hiddo J. L.
    [J]. NATURE REVIEWS NEPHROLOGY, 2020, 16 (08) : 433 - 434
  • [2] SGLT2 INHIBITORS VS. GLP1 AGONISTS AS TREATMENTS FOR OSTEOARTHRITIS
    Jafarzadeh, S. Reza
    Ma, Kevin
    Peloquin, Christine E.
    Felson, David
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S41 - S42
  • [3] Differential cardiovascular and renal benefits of SGLT2 inhibitors and GLP1 receptor agonists in patients with type 2 diabetes mellitus
    Kim, Chee Hae
    Hwang, In-Chang
    Choi, Hong-Mi
    Ahn, Chang Ho
    Yoon, Yeonyee E.
    Cho, Goo-Yeong
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 364 : 104 - 111
  • [4] RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 INHIBITORS
    Maroto, Alba
    Vidas, Maria Marques
    Sanz, Ignacio
    Lopez, Paula
    Portoles, Jose' M.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1331 - 1331
  • [5] Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
    Sridhar, Vikas S.
    Dubrofsky, Lisa
    Boulet, Jacinthe
    Cherney, David Z.
    [J]. JORNAL BRASILEIRO DE NEFROLOGIA, 2020, 42 (04): : 467 - 477
  • [6] DIABETES MEDICATION DECISION SUPPORT IN GIM: INCREASING PRESCRIPTIONS OF SGLT2 INHIBITORS AND GLP1 AGONISTS
    Hilgeman, Brian C.
    Kastner, Mandy
    MacKinney, Theodore
    Maguire, Ann
    Mendez, Carlos
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2021, 36 (SUPPL 1) : S413 - S413
  • [7] Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists JACC Focus Seminar
    Wilcox, Tanya
    De Block, Christophe
    Schwartzbard, Arthur Z.
    Newman, Jonathan D.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (16) : 1956 - 1974
  • [8] COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS VERSUS GLP1 AGONISTS ON PREVENTING POST-TRAUMATIC OSTEOARTHRITIS
    Jafarzadeh, S. Reza
    Peloquin, Christine E.
    Felson, David
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2024, 32 : S595 - S595
  • [9] Acceptance of Recommendations for SGLT2 Inhibitors and GLP1 Receptor Agonists in a High-Risk CKD Population
    Weltman, Melanie R.
    Jhamb, Manisha
    Yabes, Jonathan
    Cai, Manqi
    Nolin, Thomas D.
    Abdel-Kader, Khaled
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 865 - 865
  • [10] The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study
    Bechlioulis, Aris
    Markozannes, Georgios
    Chionidi, Ifigeneia
    Liberopoulos, Evangelos
    Naka, Katerina K.
    Ntzani, Evangelia E.
    Liatis, Stavros
    Rizzo, Manfredi
    Rizos, Evangelos C.
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (04)
12345